Lallemand Acquires Cutting-Edge Equipment for New Probiotics

Advanced Microbiome Diagnostics

Lallemand announced that the company had obtained a variety of state-of-the-art equipment that will assist them with creating drug products and drug substances in anaerobic conditions, following the closure of Bacthera’s CDMO activities.¹ The press release mentioned that some of the acquired equipment received included advanced analytical devices. For example, Q-PCR and MALDO-TOF. With these devices, it will help Expert’Biome grow their activities for LBP CDMO.

“Expert’Biome will provide a wide range of services at a GMP pharma-accredited site, including drug substance development from 480L to 17,000L in both aerobic and anaerobic conditions; Live Biotherapeutic products manufacturing in sachets, capsules and blisters; and advanced analytical tools, including classical plating technologies and new approaches for multi-strain products such as PMA-PCR, flow cytometry, and MALDI-TOF,” Stephan Griffoulière, Operations Vice-President, elaborates.¹ “This investment dedicated to the French GMP pharma plant Saint-Simon, positions Expert’Biome^TM as one of the global leaders in the live biotherapeutics industry.”

Laurie Rey, Head of CDMO Business Development at Lallemand Health Solutions saic, “These newly acquired cutting-edge technologies, together with the extension of our R&D laboratories by more than 800m², and paired with its in-house Microbiome Program dedicated to developing next-generation probiotics, give Lallemand a competitive edge.”¹

With the organization’s Microbiome Program, skills and methods are able to be improved upon to further grow the creation of bioprocesses and strains, such as those seen with strict anaerobes.

Jérôme Panes, President and General Manager at Lallemand Health Solutions explained, “With this recent acquisition and ongoing investments in our Saint-Simon plant, EXPERT’Biome^TM, is well-positioned to support our partners from early development stages through clinical batches to commercial supply in a highly competitive and specialized market. Our expertise combined with the acquired cutting-edge technologies makes EXPERT’Biome^TM one of the world leaders in the field of LBP and probiotics.”¹

The Beginnings of The Microbiome Program

In October 2023, Lallemand Health Solutions announced that they were launching a program called Expert’Biome CDMO by Lallemand, officially spanning services such as research and development of microbial strains, bioprocesses scaling, drug manufacturing, and production development..²

The company called this a strategic move that will strengthen its position in the microbiome market. “Expert’Biome leverages 90 years of know-how, from research and development to pilot-scale production and commercial manufacturing for microorganisms, and uses cutting-edge technologies and innovative scientific approaches to pioneer next-generation strains,” stated Jérôme Panes, president and general manager of Lallemand Health Solutions.²

The new Expert’Biome division is led by head of business development Laurie Rey, who holds a PhD in molecular biology. Rey noted, “The microbiome is taking on new significance, as evidenced by increased research and development and commercial success. Between 2021 and 2023, there has been a 24% increase in ongoing development trials worldwide, along with an 18% increase in countries with products in development targeting the microbiome. Over the past two years, several regulatory approvals have paved the way for next-generation microbiome strains as potential drugs to improve well-being in various health areas.”¹

New Oral Probiotic Created

Lallemand highlighted in a May 2025 press release, the creation of a new oral care probiotic.³ The strain in the new oral care probiotic is called Streptococcus salivarius (SALI-10). Ostia Sciences is looking to begin clinical trials regarding oral health applications. As mentioned in the press release,³ pre-clinical findings found that “this strain produces a bacteriocin, named Salivaricin 10, the world’s first phosphorylated lantibiotic, which will be tested in clinical trials to evaluate its ability to maintain a healthy oral microbiome, in addition to other beneficial effects such as supporting a healthy immune response.”

References

1. EXPERT’Biome, CDMO By Lallemand, Acquires Bacthera Equipment and Strengthens Its Leading Position in the Live Biotherapeutics Market https://lallemand-health-solutions.com/en/news-trends/press-releases/expertbiometm-cdmo-by-lallemand-acquires-bacthera-equipment-and-strengthens-its-leading-position-in-the-live-biotherapeutics-market/ (accessed Sep 11, 2025).
2. Grebow, J. Lallemand launches expert’biome R&D and other services for Microbiome Ingredients https://www.nutritionaloutlook.com/view/lallemand-launches-expert-biome-r-d-and-other-services-for-microbiome-ingredients (accessed Sep 11, 2025).
3. Colli, M. New Oral Care Probiotic created by Ostia Sciences and Expert’biome CDMO by Lallemand https://www.nutritionaloutlook.com/view/new-oral-care-probiotic-created-by-ostia-sciences-and-expert-biome-cdmo-by-lallemand (accessed Sep 11, 2025).